Study type: Human research · Status: Evidence verified by machine against declared source
A positive effect of Cerebrolysin on motor functions and spasticity in ALS with limb or bulbar onset is questionable
Journal of medicine and life · 2024
Study scale: Not reported in the declared source.
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Public plain-language summary
Some fields are not published, because the text held for them did not answer their heading. The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.
Research question
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study design
Not reported in the declared source.
Participants or experimental system
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Study scale
Not reported in the declared source.
Intervention or exposure
Since maintenance of functional level over a longer period is not uncommon in patients with ALS, depending on the stage of the disease, it is conceivable that maintenance of functional level simply represents the natural disease course and not a presumed treatment effect.
Comparator
Including a cross-over design where patients in the control group receive Cerebrolysin after the initial three-month period would strengthen the evidence for the effectiveness of Cerebrolysin.
Outcomes examined
This information is crucial as these factors can influence motor function and performance on outcome measures like walking tests.
Key findings
Not published. The text held for this field did not answer this heading, so nothing is shown here and nothing is substituted for it.
Limitations and uncertainty
However, several limitations in the study design warrant discussion as they may influence the interpretation of the results.
Product relevance and evidence boundary
This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.
Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.